United States securities and exchange commission logo





                           August 9, 2021

       Nancy Lurker
       Chief Executive Officer
       EyePoint Pharmaceuticals, Inc.
       480 Pleasant Street
       Watertown, MA 02472

                                                        Re: EyePoint
Pharmaceuticals, Inc.
                                                            Registration
Statement on Form S-3
                                                            Filed August 6,
2021
                                                            File No. 333-258598

       Dear Ms. Lurker:

              This is to advise you that we have not reviewed and will not
review your registration
       statement.

               Please refer to Rules 460 and 461 regarding requests for
acceleration. We remind you
       that the company and its management are responsible for the accuracy and
adequacy of their
       disclosures, notwithstanding any review, comments, action or absence of
action by the staff.

                                                        Please contact Jane
Park at 202-551-7439 with any questions.




                           Sincerely,


                           Division of Corporation Finance

                           Office of Life Sciences
       cc:                                              Stephen Nicolai, Esq.